Welcome to our dedicated page for ELUTIA SEC filings (Ticker: ELUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elutia Inc. filings document the regulatory record for a medical technology company developing and commercializing drug-eluting biomatrix products. Form 8-K reports cover financial results, preliminary operating updates, Nasdaq listing notices and compliance events, and material compensation actions tied to the company's Class A common stock.
Proxy materials disclose board matters, executive compensation, equity-award information, shareholder voting items, and governance practices. The filing record also includes disclosures on inducement award plans, stock-based compensation capacity, registered securities on the Nasdaq Capital Market, and emerging growth company status.
Elutia Inc.'s Chief Financial Officer, Matthew Ferguson, reported buying additional company stock. On 12/17/2025, he purchased 60,000 shares of Elutia Inc. Class A common stock in an open market transaction coded as a purchase, at a weighted average price of $0.53 per share, with individual trade prices ranging from $0.51 to $0.54.
Following this transaction, Ferguson beneficially owns 447,110 shares of Elutia Inc. common stock, held directly. The filing notes that detailed breakdowns of the number of shares purchased at each separate price within the reported range are available upon request to the company, any security holder, or SEC staff.
Elutia Inc. director and 10% owner Kevin Rakin filed an amended insider ownership report describing an in-kind distribution of Class A common stock from HighCape investment entities on December 11, 2025.
On that date, HighCape Partners, L.P., HighCape Partners QP, L.P., HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC distributed all of their Elutia Class A shares to their partners and members pro rata, without payment of consideration. Rakin received 126,120 shares directly and his irrevocable trusts received 181,612 shares. The filing states that the distribution resulted in a change in the form of his beneficial ownership only.
Footnotes explain Rakin’s indirect holdings through multiple HighCape-affiliated entities and trusts, and the amendment corrects an earlier Form 4 that had misstated the number of shares distributed by the HighCape entities.
Elutia Inc. director and 10% owner Kevin Rakin reported a pro rata distribution of Class A common stock on 12/11/2025. HighCape investment entities distributed 4,372,497 shares of Elutia Class A stock to their partners and members without payment of consideration.
As part of this distribution, Rakin personally received 126,120 shares and his irrevocable trusts received 181,612 shares. Following the transaction, he beneficially owns 4,978,978 Elutia shares through various HighCape entities and trusts, and the distribution is described as being without payment of consideration and as a change in the form of his beneficial ownership only.
Elutia Inc. chief scientific officer Michelle LeRoux Williams reported routine equity compensation activity. On 12/10/2025, 12,500 restricted stock units converted into shares of Class A common stock, increasing her direct holdings. The company then withheld 3,951 shares at $ 0.7 per share to cover tax obligations, leaving her with 101,934 Class A shares held directly and 50,000 restricted stock units outstanding.
These vested units are part of a 150,000 restricted stock unit grant dated 01/31/2024, which vests in scheduled installments from 06/10/2024 through 12/10/2026.
Elutia Inc.'s chief financial officer Matthew Ferguson reported equity awards activity on December 10, 2025. He acquired 12,500 shares of Class A common stock upon vesting of restricted stock units, with 4,461 shares withheld by the company to satisfy tax withholding requirements.
After these transactions, Ferguson directly owned 387,110 shares of Elutia Class A common stock and held 50,000 restricted stock units as derivative securities. The vested units are part of a 150,000-unit restricted stock grant awarded on January 31, 2024 that vests as to 1/6 on June 10, 2024 and as to 1/12 quarterly through December 10, 2026.
Elutia Inc. President, CEO and director C. Randal Mills reported the vesting of 27,083 restricted stock units into shares of the company’s Class A common stock on December 10, 2025. After this transaction, he directly owned 376,204 Class A shares and 270,833 restricted stock units.
Of the shares delivered at vesting, 9,664 shares were withheld by Elutia to satisfy tax withholding requirements, with the remaining shares retained by Mills. The filing notes that these units are part of a 487,500‑unit restricted stock grant awarded on January 31, 2024, which vests over time and upon the stock reaching price targets of $6.00, $10.00, $14.00 and $18.00 for twenty consecutive trading days, subject to his continued employment and the company’s trading‑window restrictions.
Elutia Inc. (ELUT) reported an insider stock purchase by its President and CEO, who is also a director. On 11/24/2025, the reporting person acquired 5,000 shares of Elutia Class A common stock in an open-market purchase at a price of $0.60 per share. Following this transaction, the reporting person beneficially owns 358,785 shares of Class A common stock in direct ownership form.
Elutia Inc. (ELUT) director David Colpman reported buying additional shares of the company’s Class A common stock. On 11/17/2025, he purchased 15,500 shares at a price of $0.74 per share. Following this transaction, he beneficially owned 18,598 shares, held as a direct ownership position. This filing reflects an insider open-market purchase rather than a sale.
Elutia Inc. (ELUT) filed its Q3 2025 10‑Q, highlighting a business refocus and discontinued operations. From continuing operations, net sales were $3,323 (thousands) versus $3,662 a year ago, with gross profit of $1,853 and a loss from operations of $5,208. Net loss from continuing operations was $383 for the quarter.
The company classified its cardiac implantable electronic device business as discontinued operations and completed its sale on October 1, 2025 for up to $88 million in cash, including $80.3 million paid at closing and $8 million in escrow for twelve months. Discontinued operations posted a quarterly net loss of $3,485. Cash and cash equivalents were $4,721 at September 30, 2025, with total liabilities of $73,325 and a warrant liability of $4,030. Management believes existing cash plus CIED sale proceeds, net of SWK debt repayment, fund operations for at least one year after issuance. On November 7, 2025, Nasdaq notified Elutia of non‑compliance with the $1.00 minimum bid price, with a 180‑day compliance period.
Elutia Inc. reported a Nasdaq bid-price deficiency. The company received notice that its Class A common stock closed below $1.00 for 30 consecutive business days, triggering non-compliance with Nasdaq Listing Rule 5550(a)(2). Trading on The Nasdaq Capital Market continues under “ELUT.”
Elutia has a 180‑day compliance period ending on May 6, 2026 to regain compliance. The company will be deemed compliant if its closing bid price is at least $1.00 for a minimum of ten consecutive business days, after which Nasdaq will confirm compliance. If unmet, Elutia may qualify for an additional 180 days if it meets other listing standards and notifies Nasdaq it may use a reverse stock split. Failing these steps could lead to delisting. Elutia plans to monitor its stock price and evaluate options.